Press Release | ERDERA Clinical Trial Call

ERDERA launches Clinical Trial Call 2026 to advance early‑phase clinical trials for rare diseases

ERDERA has opened its Clinical Trial Call 2026, a funding opportunity for multinational early-phase interventional clinical trials in rare diseases.

The call supports sponsor-led Phase I, Phase I/II and Phase II trials of medicinal products designed to generate robust clinical evidence, strengthen regulatory readiness and improve trial feasibility across countries.

Up to €30 million is dedicated to the call, with individual project budgets broadly expected in the range of €1 million to €5 million.

Acces this publication

publication

ERDERA clinical trial call

Year of publication

2026

Source

ERDERA

Author

ERDERA

You might also be interested in

Genetic Mapping

New clinical trial guidance supports research beyond the hospital

New international guidance supports decentralised clinical trials, pragmatic designs and the use of real-world data.
State of the art rare disease country reports ERDERA 2025

State of the art 2025 rare disease country report: Cyprus

This 2025 country report outlines the policy, research, care and support landscape for rare diseases in Cyprus.
generic scientific publication image

Leveraging precompetitive collaborations for rare diseases

The editorial examines how shared frameworks, data standards, infrastructure and governance can help stakeholders address common barriers in rare disease research and medicine development.
Engaging children, adolescents and young adults living with rare diseases as research partners: practical considerations for meaningful involvement

Engaging children, adolescents and young adults living with rare diseases as research partners: practical considerations for meaningful involvement

An International Rare Diseases Research Consortium (IRDiRC) working group developed practical guidance and a checklist for involving young people meaningfully in rare disease research.

ERDERA Search